Express Scripts’ Formulary Management Process
Clinical appropriateness, not the cost of a drug, is the first consideration in formulary decisions, said Katie Thompson and Katie Deckelbaum of Express Scripts.
Express Scripts’ formulary development team takes a proactive approach to tracking the drug pipeline to understand the new therapies that may become available and their market impact. Clinical and business teams are reviewing the data in the literature and working to understand the financial impact of those new therapies, Katie Thompson, Pharm.D., senior director, formulary solutions at Express Scripts said at the 2021 Pharmacy Benefit Management Institute® Annual National Conference.
Katie Thompson
“We are not waiting for a drug to be approved to begin the process. We know our clients expect us to be ready for what’s coming next. We want to be able to understand what formulary strategies we can implement and what clinical programs we can devise,” she said.
Express Scripts is also having conversations earlier with pharmaceutical companies to better understand the data they have, what prescribers they are interfacing with and where they see the drug fitting in, especially in categories where there will be significant impact.
Kate Deckelbaum
The organization employs a multilayer process to determine which therapies are appropriate and to include on its various formularies. “We are plan sponsors and health plans to provide affordable access to clinically sound, high-quality pharmaceuticals. Formulary management is one way to achieve this result. We are always looking for ways to unlock new value but we need to balance care and cost.”
She stressed that clinical reviewers in both the internal therapeutic assessment committee and the external P&T committee make formulary recommendations based on clinical review only and they don’t have take contracts or rebates into consideration. A separate team, the value assessment committee, makes those considerations, and firewalls exist between the clinical and the value assessment committees.
The organization employs a continuous monitoring process to be up-to-date on the latest clinical research and guidelines. “Doing right by our patients and doing right by our clients is of utmost importance,” said Kate Deckelbaum, RPh, VP, consultant relations at Express Scripts.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Group Purchasing Organizations of 'Big 3' PBMs Cloud Transparency, Says Critic | PBMI 2024
September 6th 2024Greg Baker, CEO of AffirmedRx, did not hold back in criticizing CVS Caremark, Optum Rx and Express Scripts and their group purchasing organizations today at the PBMI Annual National Conference.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
